California Institute of Technology

Indi Molecular, Inc.

Arundhati Nag

James R Heath

Samir Das

Heather Dawn Agnew

Rosemary Dyane Rohde

Steven Wesley Millward

Ryan K Henning

Paul Edward Kearney

Blake Farrow

Bert Tsunyin Lai

Suresh Mark Pitram

Aiko Umeda

Kaycie Deyle

Ashwin N Ram

David Bunck

Jingxin Liang

Joseph O Varghese

Paul Kearney

The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making

The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.

Phosphorylated Akt-specific capture agents, compositions, and methods of using and making

Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, L, L, G, M, YYand SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.

Cyclic peptides as protein targeting agents

Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pm), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.

Cyclic peptide binder against oncogenic K-Ras

The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

IL-17F-specific capture agents, compositions, and methods of using and making

The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.

Akt-specific capture agents, compositions, and methods of using and making

Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pra), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.

Multi-ligand capture agents comprising two or more ligands are described, and related compositions, methods and systems.

Capture agents and related compositions, methods and systems

The present disclosure relates to capture agents for the detection and/or separation of one or more targets in a sample. Described herein are multi-ligand capture agents comprising two or more ligands, and related compositions, methods and systems. In certain embodiments, the capture agents disclosed herein can be used for performing assays, including but not limited to assays for the detection and/or separation of targets.

Growing community of inventors

Pasadena, CA, United States of America

Arundhati Nag